Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 4
2005 3
2006 3
2007 6
2008 8
2009 4
2010 8
2011 7
2012 14
2013 13
2014 11
2015 5
2016 3
2017 3
2018 1
2019 6
2020 3
2021 3
2022 1
2023 5
2024 8
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Free article. Clinical Trial.
Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.
Matsubara N, Miura Y, Nishiyama H, Taoka R, Kojima T, Shimizu N, Hwang J, Ote T, Oyama R, Toyoizumi K, Mukhopadhyay S, Triantos S, Deprince K, Loriot Y. Matsubara N, et al. Among authors: shimizu n. Int J Clin Oncol. 2024 Oct;29(10):1516-1527. doi: 10.1007/s10147-024-02583-3. Epub 2024 Jul 17. Int J Clin Oncol. 2024. PMID: 39017806 Free PMC article. Clinical Trial.
Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.
Kato T, Hirama H, Kamoto T, Goto T, Fujimoto H, Sakamoto S, Shinohara N, Egawa S, Kouguchi D, Nakayama M, Hashine K, Shimizu N, Inoue K, Habuchi T, Hioka T, Shiraishi T, Sugimoto M, Kakehi Y. Kato T, et al. Among authors: shimizu n. Int J Clin Oncol. 2024 Oct;29(10):1557-1563. doi: 10.1007/s10147-024-02590-4. Epub 2024 Aug 1. Int J Clin Oncol. 2024. PMID: 39085727
Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H. Kato T, et al. Among authors: shimizu n. Int J Urol. 2024 Mar;31(3):265-272. doi: 10.1111/iju.15345. Epub 2023 Dec 18. Int J Urol. 2024. PMID: 38110838 Free PMC article.
Erdafitinib versus Chemotherapy in Fibroblast Growth Factor Receptor-Altered Advanced or Metastatic Urothelial Cancer After Progression on Anti-programmed Death-(Ligand) 1 Therapy: An Exploratory Analysis of the Asian Subpopulation in the THOR Phase 3 Study.
Matsubara N, Loriot Y, Burgess EF, Park SH, Huddart RA, Ku JH, Tran B, Huang J, Huang YH, Nishimura K, Shimizu N, Xing N, Xue W, Hemaya R, Zhuo J, Deprince K, Triantos S, Siefker-Radtke AO. Matsubara N, et al. Among authors: shimizu n. Clin Genitourin Cancer. 2025 Aug;23(4):102376. doi: 10.1016/j.clgc.2025.102376. Epub 2025 May 14. Clin Genitourin Cancer. 2025. PMID: 40483179 Free article. Clinical Trial.
93 results